Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.

Xiao Y, Liu R, Li X, Gurley EC, Hylemon PB, Lu Y, Zhou H, Cai W.

Hepatology. 2019 May 7. doi: 10.1002/hep.30698. [Epub ahead of print]

PMID:
31063660
2.

The role of sphingosine kinase 2 in alcoholic liver disease.

Kwong EK, Liu R, Zhao D, Li X, Zhu W, Wang X, Gurley EC, Lai G, Liu J, Hylemon PB, Zhou H.

Dig Liver Dis. 2019 Apr 16. pii: S1590-8658(19)30526-2. doi: 10.1016/j.dld.2019.03.020. [Epub ahead of print]

PMID:
31003959
3.

Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.

Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurley EC, Liang G, Chen W, Lai G, Pandak WM, Robert Lippman H, Bajaj JS, Hylemon PB, Zhou H.

Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662. [Epub ahead of print]

PMID:
30985008
4.

Alterations in Skin Microbiomes of Patients With Cirrhosis.

Bajaj JS, Fagan A, Sikaroodi M, Kakiyama G, Takei H, Degefu Y, Pandak WM, Hylemon PB, Fuchs M, John B, Heuman DM, Gavis E, Nittono H, Patil R, Gillevet PM.

Clin Gastroenterol Hepatol. 2019 Mar 21. pii: S1542-3565(19)30292-7. doi: 10.1016/j.cgh.2019.03.028. [Epub ahead of print]

PMID:
30905718
5.

Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.

Bajaj JS, Fagan A, White MB, Wade JB, Hylemon PB, Heuman DM, Fuchs M, John BV, Acharya C, Sikaroodi M, Gillevet PM.

Am J Gastroenterol. 2019 Jan 28. doi: 10.14309/ajg.0000000000000102. [Epub ahead of print]

PMID:
30816877
6.

Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols.

Kakiyama G, Marques D, Takei H, Nittono H, Erickson S, Fuchs M, Rodriguez-Agudo D, Gil G, Hylemon PB, Zhou H, Bajaj JS, Pandak WM.

J Steroid Biochem Mol Biol. 2019 May;189:36-47. doi: 10.1016/j.jsbmb.2019.01.011. Epub 2019 Jan 30.

PMID:
30710743
7.

Effect of Increasing Age on Brain Dysfunction in Cirrhosis.

Liu R, Ahluwalia V, Kang JD, Ghosh SS, Zhou H, Li Y, Zhao D, Gurley E, Li X, White MB, Fagan A, Lippman HR, Wade JB, Hylemon PB, Bajaj JS.

Hepatol Commun. 2018 Nov 30;3(1):63-73. doi: 10.1002/hep4.1286. eCollection 2019 Jan.

8.

Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids.

Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, Zhou H, Hylemon PB.

Cell Chem Biol. 2019 Jan 17;26(1):27-34.e4. doi: 10.1016/j.chembiol.2018.10.003. Epub 2018 Oct 25.

PMID:
30482679
9.

Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation.

Liu R, Li X, Hylemon PB, Zhou H.

Am J Pathol. 2018 Sep;188(9):2042-2058. doi: 10.1016/j.ajpath.2018.05.015. Epub 2018 Jun 30.

PMID:
29963993
10.

Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.

Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM.

Am J Gastroenterol. 2018 Aug;113(8):1177-1186. doi: 10.1038/s41395-018-0085-9. Epub 2018 Jun 6.

PMID:
29872220
11.

Reply.

Bajaj JS, Savidge T, Kassam ZA, Hylemon PB, Gillevet PM.

Hepatology. 2018 Sep;68(3):1206. doi: 10.1002/hep.30092. No abstract available.

PMID:
29774575
12.

Metabolism of hydrogen gases and bile acids in the gut microbiome.

Hylemon PB, Harris SC, Ridlon JM.

FEBS Lett. 2018 Jun;592(12):2070-2082. doi: 10.1002/1873-3468.13064. Epub 2018 May 7. Review.

13.

Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, Gavis EA, Pandak WM, Nittono H, Hylemon PB, Boonma P, Haag A, Heuman DM, Fuchs M, John B, Sikaroodi M, Gillevet PM.

Hepatology. 2018 Oct;68(4):1549-1558. doi: 10.1002/hep.30037. Epub 2018 Sep 20.

PMID:
29665102
14.

Bile acid oxidation by Eggerthella lenta strains C592 and DSM 2243T.

Harris SC, Devendran S, Méndez-García C, Mythen SM, Wright CL, Fields CJ, Hernandez AG, Cann I, Hylemon PB, Ridlon JM.

Gut Microbes. 2018 Nov 2;9(6):523-539. doi: 10.1080/19490976.2018.1458180. Epub 2018 May 24.

15.

Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.

Bajaj JS, Thacker LR, Fagan A, White MB, Gavis EA, Hylemon PB, Brown R, Acharya C, Heuman DM, Fuchs M, Dalmet S, Sikaroodi M, Gillevet PM.

JCI Insight. 2018 Mar 8;3(5). pii: 98019. doi: 10.1172/jci.insight.98019.

16.

Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.

Li X, Liu R, Huang Z, Gurley EC, Wang X, Wang J, He H, Yang H, Lai G, Zhang L, Bajaj JS, White M, Pandak WM, Hylemon PB, Zhou H.

Hepatology. 2018 Aug;68(2):599-615. doi: 10.1002/hep.29838. Epub 2018 May 2.

PMID:
29425397
17.

Gut microbial composition can differentially regulate bile acid synthesis in humanized mice.

Kang DJ, Hylemon PB, Gillevet PM, Sartor RB, Betrapally NS, Kakiyama G, Sikaroodi M, Takei H, Nittono H, Zhou H, Pandak WM, Yang J, Jiao C, Li X, Lippman HR, Heuman DM, Bajaj JS.

Hepatol Commun. 2017 Feb 27;1(1):61-70. doi: 10.1002/hep4.1020. eCollection 2017 Feb.

18.

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort.

Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D, White MB, Karakaya F, Wang J, Atalay R, Hylemon PB, Gavis EA, Brown R, Thacker LR, Acharya C, Heuman DM, Sikaroodi M, Gillevet PM.

Hepatology. 2018 Jul;68(1):234-247. doi: 10.1002/hep.29791. Epub 2018 May 10.

PMID:
29350768
19.

Gut-liver axis alterations in alcoholic liver disease: Are bile acids the answer?

Bajaj JS, Hylemon PB.

Hepatology. 2018 Jun;67(6):2074-2075. doi: 10.1002/hep.29760. Epub 2018 Apr 19. No abstract available.

PMID:
29272041
20.

Identification of a gene encoding a flavoprotein involved in bile acid metabolism by the human gut bacterium Clostridium scindens ATCC 35704.

Harris SC, Devendran S, Alves JMP, Mythen SM, Hylemon PB, Ridlon JM.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Mar;1863(3):276-283. doi: 10.1016/j.bbalip.2017.12.001. Epub 2017 Dec 5.

PMID:
29217478
21.

Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.

Kwong EK, Li X, Hylemon PB, Zhou H.

Curr Pharmacol Rep. 2017 Aug;3:176-183. doi: 10.1007/s40495-017-0093-2. Epub 2017 Jun 20.

22.

Bile acids as global regulators of hepatic nutrient metabolism.

Hylemon PB, Takabe K, Dozmorov M, Nagahashi M, Zhou H.

Liver Res. 2017 Jun;1(1):10-16. doi: 10.1016/j.livres.2017.03.002. Epub 2017 Apr 26.

23.

Cordycepin inhibits LPS-induced inflammatory responses by modulating NOD-Like Receptor Protein 3 inflammasome activation.

Yang J, Li YZ, Hylemon PB, Zhang LY, Zhou HP.

Biomed Pharmacother. 2017 Nov;95:1777-1788. doi: 10.1016/j.biopha.2017.09.103. Epub 2017 Oct 6.

PMID:
28962083
24.

C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice.

Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, Pandak WM, Hylemon PB, Bajaj JS, Sanyal AJ, Zhou H.

Hepatology. 2018 Apr;67(4):1441-1457. doi: 10.1002/hep.29540. Epub 2018 Feb 19.

25.

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.

Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ.

Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359. [Epub ahead of print]

26.

Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats.

Yang J, Sun L, Wang L, Hassan HM, Wang X, Hylemon PB, Wang T, Zhou H, Zhang L, Jiang Z.

Front Pharmacol. 2017 May 9;8:260. doi: 10.3389/fphar.2017.00260. eCollection 2017.

27.

The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.

Li X, Liu R, Yang J, Sun L, Zhang L, Jiang Z, Puri P, Gurley EC, Lai G, Tang Y, Huang Z, Pandak WM, Hylemon PB, Zhou H.

Hepatology. 2017 Sep;66(3):869-884. doi: 10.1002/hep.29145. Epub 2017 Jul 20.

28.

The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.

Wang Y, Aoki H, Yang J, Peng K, Liu R, Li X, Qiang X, Sun L, Gurley EC, Lai G, Zhang L, Liang G, Nagahashi M, Takabe K, Pandak WM, Hylemon PB, Zhou H.

Hepatology. 2017 Jun;65(6):2005-2018. doi: 10.1002/hep.29076. Epub 2017 Apr 28.

29.

Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis.

Bajaj JS, Ahluwalia V, Steinberg JL, Hobgood S, Boling PA, Godschalk M, Habib S, White MB, Fagan A, Gavis EA, Ganapathy D, Hylemon PB, Stewart KE, Keradman R, Liu EJ, Wang J, Gillevet PM, Sikaroodi M, Moeller FG, Wade JB.

Sci Rep. 2016 Dec 6;6:38481. doi: 10.1038/srep38481.

30.

Sphingosine-1 phosphate promotes intestinal epithelial cell proliferation via S1PR2.

Chen T, Huang Z, Liu R, Yang J, Hylemon PB, Zhou H.

Front Biosci (Landmark Ed). 2017 Jan 1;22:596-608.

PMID:
27814635
31.

Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.

Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P.

J Biol Chem. 2016 Sep 23;291(39):20823. doi: 10.1074/jbc.A116.803444. No abstract available.

32.

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.

Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS.

Clin Transl Gastroenterol. 2016 Aug 25;7(8):e187. doi: 10.1038/ctg.2016.44.

33.

The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases.

Nagahashi M, Yuza K, Hirose Y, Nakajima M, Ramanathan R, Hait NC, Hylemon PB, Zhou H, Takabe K, Wakai T.

J Lipid Res. 2016 Sep;57(9):1636-43. doi: 10.1194/jlr.R069286. Epub 2016 Jul 26. Review.

34.

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.

Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, Daita K, Heuman DM, Sikaroodi M, Hylemon PB, White MB, Ganapathy D, Gillevet PM.

Aliment Pharmacol Ther. 2016 Sep;44(6):638-43. doi: 10.1111/apt.13732. Epub 2016 Jul 15.

35.

Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, Sanyal AJ, Heuman DM, Carl D, Zhou H, Liu R, Wang X, Yang J, Jiao C, Herzog J, Lippman HR, Sikaroodi M, Brown RR, Bajaj JS.

Hepatology. 2016 Oct;64(4):1232-48. doi: 10.1002/hep.28696. Epub 2016 Jul 29.

36.

Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis.

Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS.

Sci Rep. 2016 May 26;6:26800. doi: 10.1038/srep26800.

37.

Role of AMP-activated protein kinase α1 in 17α-ethinylestradiol-induced cholestasis in rats.

Li X, Liu R, Luo L, Yu L, Chen X, Sun L, Wang T, Hylemon PB, Zhou H, Jiang Z, Zhang L.

Arch Toxicol. 2017 Jan;91(1):481-494. doi: 10.1007/s00204-016-1697-8. Epub 2016 Apr 18.

38.

Consequences of bile salt biotransformations by intestinal bacteria.

Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB.

Gut Microbes. 2016;7(1):22-39. doi: 10.1080/19490976.2015.1127483. Review.

39.

Erratum: Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.

Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM.

Sci Rep. 2016 Jan 29;6:20447. doi: 10.1038/srep20447. No abstract available.

40.

Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.

Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM.

Sci Rep. 2015 Dec 22;5:18559. doi: 10.1038/srep18559. Erratum in: Sci Rep. 2016;6:20447.

41.

Structure and functional characterization of a bile acid 7α dehydratase BaiE in secondary bile acid synthesis.

Bhowmik S, Chiu HP, Jones DH, Chiu HJ, Miller MD, Xu Q, Farr CL, Ridlon JM, Wells JE, Elsliger MA, Wilson IA, Hylemon PB, Lesley SA.

Proteins. 2016 Mar;84(3):316-31. doi: 10.1002/prot.24971. Epub 2016 Jan 18.

42.

Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.

Kwong E, Li Y, Hylemon PB, Zhou H.

Acta Pharm Sin B. 2015 Mar;5(2):151-7. doi: 10.1016/j.apsb.2014.12.009. Epub 2015 Feb 9. Review.

43.

Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

Liu R, Li X, Qiang X, Luo L, Hylemon PB, Jiang Z, Zhang L, Zhou H.

J Biol Chem. 2015 Dec 25;290(52):30988-1002. doi: 10.1074/jbc.M115.668277. Epub 2015 Oct 30.

44.

Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models.

Kang DJ, Hylemon PB, Bajaj JS.

Ann Hepatol. 2015 Sep-Oct;14(5):762-3. No abstract available.

45.

Reply.

Bajaj JS, Zhou H, Kang DJ, Hylemon PB.

Hepatology. 2016 May;63(5):1736-7. doi: 10.1002/hep.27952. Epub 2015 Aug 3. No abstract available.

PMID:
26105621
46.

Astrocyte Elevated Gene-1 (AEG-1) Regulates Lipid Homeostasis.

Robertson CL, Srivastava J, Siddiq A, Gredler R, Emdad L, Rajasekaran D, Akiel M, Shen XN, Corwin F, Sundaresan G, Zweit J, Croniger C, Gao X, Ghosh S, Hylemon PB, Subler MA, Windle JJ, Fisher PB, Sarkar D.

J Biol Chem. 2015 Jul 17;290(29):18227-36. doi: 10.1074/jbc.M115.661801. Epub 2015 Jun 11.

47.

Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.

Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS.

Dig Dis. 2015;33(3):338-45. doi: 10.1159/000371678. Epub 2015 May 27.

48.

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.

Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM.

Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.

49.

Correction: A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.

Gu S, Cao B, Sun R, Tang Y, Paletta JL, Wu XL, Liu L, Zha W, Zhao C, Li Y, Ridlon JM, Hylemon PB, Zhou H, Aa J, Wang G.

Mol Biosyst. 2015 Feb;11(2):664. doi: 10.1039/c4mb90042a. Epub 2014 Dec 23.

PMID:
25535027
50.

A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.

Gu S, Cao B, Sun R, Tang Y, Paletta JL, Wu X, Liu L, Zha W, Zhao C, Li Y, Ridlon JM, Hylemon PB, Zhou H, Aa J, Wang G.

Mol Biosyst. 2015 Feb;11(2):463-74. doi: 10.1039/c4mb00500g. Epub 2014 Nov 20. Erratum in: Mol Biosyst. 2015 Feb;11(2):664. Wu, Xiao-Lei [corrected to Wu, Xiaolei]; Radlon, Jason M [corrected to Ridlon, Jason M].

Supplemental Content

Loading ...
Support Center